David Whellan
Cardiovascular Disease · Philadelphia, PANPI 1184647794
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $75,625 of the $77,888 with a category attached, or 97.1%. Cvrx, Inc. accounts for 95.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $22,225 and has fallen 94.8% since, to $1,163 in 2023. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $1693.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$74K
- Novo Nordisk$1K
- Amgen$1K
- Novartis$1K
- Alnylam Pharmaceuticals Inc.$35
- AstraZeneca$22
- plus $12 from 1 others
Across 33 payments — averaging $4033.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$57K
- Resmed Corp$42K
- Amgen$17K
- Merck$5K
- Novo Nordisk AS$5K
- Novo Nordisk$5K
- plus $3K from 2 others
What the payments were for
- Consulting fees$75,62597%
- Travel & lodging$1,8182%
- Food & beverage$4091%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 29 | $74,463 |
| Novo Nordisk | 1 | $1,163 |
| Amgen | 9 | $1,115 |
| Novartis | 4 | $1,078 |
| Alnylam Pharmaceuticals Inc. | 1 | $35 |
| AstraZeneca | 1 | $22 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$74,463
- RYBELSUS$1,163
- ENTRESTO$495
How this compares
$77,888 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.